

Cadila Pharma sets new standard in migraine management with Vasograin Plus

05 August 2025 | News

Combining the benefits of a selective serotonin receptor agonist and a non-steroidal anti-inflammatory agent



Ahmedabad-based Cadila Pharmaceuticals has launched Vasograin Plus, a novel, dual-action formulation designed for the acute treatment of migraines with or without aura in both adults and adolescents.

Vasograin Plus represents a major advancement in the treatment of migraine, a condition that affects millions globally and significantly influences quality of life. It is a unique therapy that combines two well-established pharmacological agents to work through complementary mechanisms, targeting both the neurological and inflammatory triggers of migraines.

It delivers rapid onset of action, longer-lasting relief, and helps reduce the likelihood of recurrence, all in a single tablet.

Vasograin Plus combines the benefits of a selective serotonin receptor agonist and a non-steroidal anti-inflammatory agent to provide dual-action relief. It effectively addresses the neurological impact by helping constrict dilated cranial blood vessels and inhibiting the pain signals triggered by the trigeminal nerve, and reducing inflammation and pain sensitivity that often prolong migraine symptoms.

This combination ensures that patients experience not only faster relief but also sustained control over migraine attacks, minimising the need for repeat doses or additional medications.

Vasograin Plus was proven to be safe, effective, and well tolerated in a comprehensive 12-month open-label study involving over 500 patients with moderate to severe migraine. The majority of migraine attacks were effectively managed with a single dose, and the treatment demonstrated a low incidence of adverse events. There were no new safety concerns, and second-dose use showed no increase in side effects.